MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study
Otilimab is a human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF) This study was done at nine sites across the USA, Poland, and Germany. Otilimab was well tolerated and showed some evidence for improved synovitis over 12 weeks.
